Company Profile
C4 Therapeutics Stock Price, News & Analysis
- Ticker:
- CCCC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.64 USD (+0.55%)
Close
Last updated: August 6, 2026
480M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, CCCC closed up 0.55% at $3.64. No new same-company headline was identified in the current news window.
Company overview
Targeted Protein Degradation Company
C4 Therapeutics develops medicines that use the cell’s protein-disposal machinery to remove disease-causing proteins.
Cemsidomide
Cemsidomide is an oral molecular glue degrader of IKZF1 and IKZF3 being developed as a potential foundational therapy for multiple myeloma.
Combination Strategy
Clinical studies combine cemsidomide with dexamethasone, elranatamab, proteasome inhibitors, and CD38 antibodies across relapsed or refractory disease.
Future catalysts
Additional cemsidomide Phase 1 analyses are scheduled for presentation at the June 2026 EHA Congress.
A Phase 1b study combining cemsidomide with approved multiple myeloma therapies is expected to begin in the first half of 2027.
Recent news
- 01
- 02
C4 Therapeutics to Participate in Upcoming Conferences
Source: C4 Therapeutics
- 03
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Source: C4 Therapeutics
- 04
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Source: C4 Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of C4 Therapeutics (CCCC)?
C4 Therapeutics (CCCC) most recently closed at 3.64 USD, a +0.55% move versus the previous session.
What is the market cap of C4 Therapeutics (CCCC)?
C4 Therapeutics currently has a market capitalization of 480M USD on BioPharmSignal.
What does C4 Therapeutics do?
Targeted Protein Degradation Company C4 Therapeutics develops medicines that use the cell’s protein-disposal machinery to remove disease-causing proteins. Cemsidomide Cemsidomide is an oral molecular glue degrader of IKZF1 and IKZF3 being developed as a potential foundational therapy for multiple myeloma. Combination Strategy Clinical studies combine...
On which exchange is CCCC stock listed?
C4 Therapeutics (CCCC) is associated with NASDAQ, United States, Biopharma.
What is elranatamab?
Combination Strategy Clinical studies combine cemsidomide with dexamethasone, elranatamab, proteasome inhibitors, and CD38 antibodies across relapsed or refractory disease.
Which conditions is C4 Therapeutics targeting with elranatamab?
Targeted Protein Degradation Company C4 Therapeutics develops medicines that use the cell’s protein-disposal machinery to remove disease-causing proteins. Cemsidomide Cemsidomide is an oral molecular glue degrader of IKZF1 and IKZF3 being developed as a potential foundational therapy for multiple myeloma. Combination Strategy Clinical studies combine...
How does C4 Therapeutics describe recent progress with elranatamab?
Additional cemsidomide Phase 1 analyses are scheduled for presentation at the June 2026 EHA Congress. A Phase 1b study combining cemsidomide with approved multiple myeloma therapies is expected to begin in the first half of 2027.
What is Targeted?
Targeted Protein Degradation Company C4 Therapeutics develops medicines that use the cell’s protein-disposal machinery to remove disease-causing proteins.